Drug Profile
Belatacept biosimilar - Alphamab
Alternative Names: KN-019Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antirheumatics; Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Renal transplant rejection; Rheumatoid arthritis
Most Recent Events
- 25 Jul 2022 Phase II development is ongoing in China (Jiangsu Alphamab Biopharmaceuticals pipeline, July 2022)
- 05 May 2022 Belatacept biosimilar - Alphamab is available for licensing as of 05 May 2022. https://www.alphamabonc.com/en/company/partnering.html
- 05 May 2022 Alphamab plans to initiate a phase III registration trial in 2022 Q4